Spots Global Cancer Trial Database for human epidermal growth factor 2 negative carcinoma of breast
Every month we try and update this database with for human epidermal growth factor 2 negative carcinoma of breast cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer | NCT03854617 | Human Epidermal... | Oral NVB Metron... Oral NVB Weekly | 18 Years - 85 Years | ChineseAMS | |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | NCT01288261 | Human Epidermal... Male Breast Can... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel bavituximab laboratory biom... pharmacological... | 18 Years - | University of Arizona | |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | NCT01905592 | Neoplasms, Brea... Carcinoma of Br... Human Epidermal... BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Neoplas... | niraparib Physician's cho... | 18 Years - | Tesaro, Inc. | |
| Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | NCT02894398 | Breast Cancer Hormone Recepto... Human Epidermal... | Palbociclib Letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | iOMEDICO AG | |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | NCT02824575 | Breast Cancer Breast Adenocar... Human Epidermal... Recurrent Breas... Stage IV Breast... | Rebastinib Paclitaxel Eribulin Mesyla... | 18 Years - | Montefiore Medical Center | |
| A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older | NCT02823262 | Breast Cancer Estrogen Recept... Node-negative B... Human Epidermal... | Breast Cancer T... Usual Care | 70 Years - | Beth Israel Deaconess Medical Center | |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | NCT02623972 | Inflammatory Br... Human Epidermal... | Eribulin Adriamycin Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) | NCT03809988 | Breast Cancer Advanced Breast... Hormone Recepto... Human Epidermal... | Palbociclib Endocrine thera... | 18 Years - | MedSIR | |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | NCT02824575 | Breast Cancer Breast Adenocar... Human Epidermal... Recurrent Breas... Stage IV Breast... | Rebastinib Paclitaxel Eribulin Mesyla... | 18 Years - | Montefiore Medical Center | |
| Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients | NCT02175446 | Metastatic Brea... Human Epidermal... | Bevacizumab and... | 18 Years - | Consorzio Oncotech | |
| A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older | NCT02823262 | Breast Cancer Estrogen Recept... Node-negative B... Human Epidermal... | Breast Cancer T... Usual Care | 70 Years - | Beth Israel Deaconess Medical Center | |
| Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. | NCT06338644 | Hormone-recepto... Human Epidermal... Metastatic Brea... | Palbociclib | 18 Years - | Helwan University | |
| Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | NCT01394211 | Estrogen Recept... Human Epidermal... Male Breast Can... Recurrent Breas... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... | anastrozole pazopanib hydro... therapeutic con... | 18 Years - | University of Arizona | |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | NCT01288261 | Human Epidermal... Male Breast Can... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel bavituximab laboratory biom... pharmacological... | 18 Years - | University of Arizona | |
| Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | NCT02404051 | Metastatic Brea... Breast Cancer Hormone Recepto... Human Epidermal... Locally Advance... | Everolimus Exemestane Fulvestrant | 18 Years - | Consorzio Oncotech | |
| Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients | NCT01885013 | Human Epidermal... | Metformin + Myo... Myocet + Cyclop... | 18 Years - 75 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer | NCT01548677 | Breast Cancer Human Epidermal... Circulating Tum... | trastuzumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. | NCT06338644 | Hormone-recepto... Human Epidermal... Metastatic Brea... | Palbociclib | 18 Years - | Helwan University | |
| Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients | NCT01885013 | Human Epidermal... | Metformin + Myo... Myocet + Cyclop... | 18 Years - 75 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer | NCT01934478 | Human Epidermal... | 18 Years - 80 Years | Qingdao Central Hospital | ||
| ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism | NCT02806817 | Breast Cancer Human Epidermal... Early-Stage Bre... | ME-344 Bevacizumab Normal saline | 18 Years - | Centro Nacional de Investigaciones Oncologicas CARLOS III |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
